Leerink Partners Maintains Outperform on Camp4 Therapeutics, Raises Price Target to $9

Benzinga Newsdesk www.benzinga.com Positive 93.1%

Neg 0% Neu 0% Pos 93.1%

Leerink Partners analyst Mani Foroohar maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform and raises the price target from $8 to $9.